EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.

被引：0
|
作者：
Emery, M. G. [1 ]
Gibbs, J. P. [1 ]
Slatter, J. G. [2 ]
Hamilton, L. [3 ]
Wasserman, S. M. [1 ]
Geller, M. [1 ]
Dias, C. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Seattle, WA USA
[3] Amgen Ltd, Uxbridge, Middx, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-034
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [21] Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C
    Kelsey, Michelle D.
    Newby, L. Kristin
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (08) : JC86 - JC86
  • [22] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [23] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [24] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    Drugs in R&D, 2021, 21 : 375 - 384
  • [25] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
  • [26] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    Critical Care, 12 (Suppl 2):
  • [27] Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
    Robert J Konrad
    Jason S Troutt
    Guoqing Cao
    Lipids in Health and Disease, 10
  • [28] Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
    Konrad, Robert J.
    Troutt, Jason S.
    Cao, Guoqing
    LIPIDS IN HEALTH AND DISEASE, 2011, 10
  • [29] PCSK9 and LDL-C Lowering Effect of SOAP Targeting siRNA in Mouse and Non-Human Primate Models
    Jensen, Kristian K.
    Tadin-Strapps, Marija
    Wang, Sheng-Ping
    Herath, Kithsiri
    Hubert, James
    Kan, Yanqing
    Rosa, Ray
    Szeto, Daphne
    Williams, Stephanie
    Xie, Dan
    Zhou, Haihong
    Forrest, Gail
    Previs, Stephen F.
    McLaren, David G.
    Sepp-Lorenzino, Laura
    Pinto, Shirly
    CIRCULATION, 2014, 130
  • [30] So low ... so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors
    Gencer, Baris
    Mach, Francois
    EUROPEAN HEART JOURNAL, 2018, 39 (05) : 382 - 384
12345